American Board of Clinical Pharmacy for Cardiology



Domain 1: Patient Management and Therapeutics (approx. 59%):

CV anatomy/physiology

  • Epidemiology, pathophysiology, risk factors, diagnosis, and treatment of the following chronic and/or acute disease states: Aortic dissection - Arrhythmias - Cardiac Tamponade - Dyslipidemia - Heart failure - Hypertension - Hypotension - Infective endocarditis - Ischemic heart disease - Myocarditis - Pericarditis - Peripheral arterial disease - Pulmonary hypertension - Shock - Thrombotic disorders - Valvular heart disease - Pharmacology, pharmacokinetics, pharmacodynamics, and pharmacogenomics of CV pharmacotherapies
  • Lifestyle modifications (e.g., smoking cessation, exercise, diet)
  • CV procedures (e.g., cardioversion, ablation, PCI, CABG, cardiac transplantation)
  • Device therapy (e.g., pacemaker, IABP, ICDs, LVADs)
  • Laboratory testing specific to cardiology (e.g., troponin, BNP, platelet testing, genomic testing, INR)
  • Diagnostic testing specific to cardiology (e.g., echo, stress testing, cardiac catheterization, ECG)
  • Drug-induced or exacerbation of CV diseases
  • Risk stratification scores
  • Hemodynamic monitoring
  • CV-specific physical assessments (e.g., weight changes, presence of edema, breath sounds)
  • Monitoring parameters for therapeutic efficacy and adverse effects of CV pharmacotherapies
  • Documentation procedures
  • Patient counseling and education techniques
  • Collaboration strategies and techniques
  • Communication strategies and techniques
  • Drug interactions with CV pharmacotherapies
  • Complementary and alternative medicines and their effects on CV health
  • Patient-specific considerations (e.g., age, gender, ethnicity, comorbidities, socioeconomic status)
  • Pharmacoeconomic considerations
  • Patient assistance programs
  • Facilitation of transitions of care

 Domain 2: Information Management and Education (approx. 23%)

  • Primary, secondary, and tertiary sources of cardiovascular-related information
  • Research design and methodology of cardiovascular-related trials
  • Biostatistical methods used in cardiovascular-related trials
  • Internal and external validity of cardiovascular-related trials
  • Cardiovascular study endpoints (e.g., composite, surrogate)
  • Opportunities for disseminating CV knowledge (e.g., publications, presentations)
  • Audience-specific medical writing
  • Roles of multidisciplinary CV team members
  • Principles and methods of educating, training and mentoring practicing pharmacists and pharmacy trainees

Domain 3: Practice Development and Administration (approx. 14%)

  • Accreditation, legal, regulatory and safety requirements related to the care of cardiovascular patients (e.g., The Joint Commission requirements, ASHP standards, Center for Medicare and Medicaid Services, National Committee for Quality Assurance, State Boards of Pharmacy, US Food and Drug Administration) Methods for identifying areas for process improvement (e.g., incident reports, chart review)
  • Quality improvement techniques/methods (e.g., MUE, root cause analysis)
  • Metrics for evaluating the value of cardiology pharmacy services (e.g., clinical, economic and patient experience)
  • Pharmacoeconomics of cardiovascular therapies
  • Clinical practice guidelines for the treatment of patients with or at risk for cardiovascular disease (e.g., AHA/ACCF, HFSA, ACCP, NHLBI)
  • Principles of formulary development and management, including strategies for managing drug shortages Capabilities and limitations of electronic health information systems
  • Methods for developing, implementing, and evaluating clinical pathways, protocols, and policies

Domain 4: Public Health and Patient Advocacy (approx. 4%)

  • CV health promotion, disease prevention, and risk reduction strategies
  • Public health information resources regarding CV health, prevention, and treatment
  • CV screening techniques and application of results
  • Healthcare delivery systems (e.g., Medicare, Medicaid, private insurance) as they impact access to care and treatment for CV patients
  • Pharmacy advocacy organizations (e.g., ASHP, ACCP, APhA)
  • Professional organizations and their roles and resources related to patient advocacy (e.g., ACC, AHA, HFSA)
  • Health literacy considerations in CV public health initiatives